Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation

American Journal of Transplantation

Volumn 12, Issue 5, 2012, Pages 1192-1198

  Liefeldt, L ^a   Brakemeier, S ^a   Glander, P ^a   Waiser, J ^a   Lachmann, N ^a   Schonemann C ^a   Zukunft, B ^a   Illigens, P ^a   Schmidt, D ^a   Wu, K ^a   Rudolph, B ^a   Neumayer, H H ^a   Budde, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antibody mediated rejection; cyclosporine; donor specific antibodies; everolimus; immunosuppression; kidney transplantation

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; HLA ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBODY SCREENING; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; SURVIVAL RATE; TISSUE DONORS; YOUNG ADULT;

EID: 84860431997     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03961.x     Document Type: Article

References (26)

1. Dunn TB, Noreen H, Gillingham K, et al,. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132-2143.
2. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al,. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804-2812.
3. Mao Q, Terasaki PI, Cai J, et al,. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five year longitudinal study. Am J Transplant 2007; 7: 864-887.
4. Lachmann N, Terasaki PI, Budde K, et al,. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513.
5. Lefaucheur C, Nochy D, Hill GS, et al,. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832-841.
6. Gloor J, Cosio F, Lager DJ, et al,. The spectrum of antibody mediated renal allograft injury: Implications for treatment. Am J Transplant 2008; 8: 1367-1373.
7. Everly MJ, Everly JJ, Arend LJ, et al,. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063-1071.
8. Loupy A, Suberbielle-Boissel C, Hill GS, et al,. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
9. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
10. Gloor JM, Sethi S, Stegall MD, et al,. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124-2132.
11. Cosio FG, Gloor JM, Sethi S, et al,. Transplant glomerulopathy. Am J Transplant 2008; 8: 492-496.
12. Sis B, Mengel M, Haas M, et al,. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
13. Hill GS, Nochy D, Bruneval P, et al,. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011; 22: 975-983.
14. Archdeacon P, Chan M, Neuland C, et al,. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11: 896-906.
15. Fotheringham J, Angel C, Goodwin J, et al,. Natural history of proteinuria in renal transplant recipients developing de novo human leukocyte antigen antibodies. Transplantation 2011; 91: 991-996.
16. Sánchez-Fructuoso AI, Santiago JL, Pérez-Flores I, et al,. De novo anti-HLA antibodies in renal allograft recipients: A cross-section study. Transplant Proc 2010; 42: 2874-2876.
17. Budde K, Becker T, Arns W, et al., ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837-847.
18. Lebranchu Y, Thierry A, Toupance O, et al,. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115-1123.
19. Guba M, Pratschke J, Hugo C, et al., SMART-Study Group. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial. Transplantation 2010; 90: 175-183.
20. Weir MR, Mulgaonkar S, Chan L, et al,. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897-907.
21. Lebranchu Y,. Can we eliminate both calcineurin inhibitors and steroids? Transplant Proc. 2010; 42 (Suppl 9): S25-S28.
22. Schröter K, Lindemann G, Fritsche L,. TBase2-a web-based electronic patient record. Fundamenta Informaticae 2000; 43: 343-353.
23. Glander P, Budde K, Schmidt D, et al,. The 'blood group O problem' in kidney transplantation-time to change? Nephrol Dial Transplant 2010; 25: 1998-2004.
24. Ferguson R, Grinyó J, Vincenti F, et al,. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11: 66-76.
25. Larsen CP, Grinyó J, Medina-Pestana J, et al,. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: Two-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90: 1528-1535.
26. Letavernier E, Pe'raldi MN, Pariente A, et al,. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80: 1198-1203.